Beckman Coulter Life Sciencesa global leader in laboratory automation and innovation and part of Danaher Corporation (NYSE: DHR), has launched the Cydem VT Automated Clone Screening System, an innovative high-throughput microbial reactor platform for automated top-clone screening.
The new Cydem VT system significantly accelerates biological drug discovery and time to market for monoclonal antibody-based therapies by reducing the manual laboratory steps of cell line development by up to 90% in a single experiment and eliminating the need for many subsequent traditional screening steps.
The Cydem VT System provides early answers about cell growth and productivity during cell line development, providing laboratories with better culture conditions closer to biomanufacturing production with more reliable clones compared to traditional methods. The all-in-one high-throughput screening platform is ideal for cell line development of Chinese hamster ovary (CHO) cell lines producing monoclonal antibodies (mAbs).
“Our Cydem VT automated clonal screening system offers an exciting revolution in expediting critical investigational treatments for diseases including autoimmune diseases and various types of cancer,” said Sebastian Hofzumahaus, Ph.D., product manager. “We heard concerns about selecting low-productivity clones and understood the critical need to develop an easy-to-use solution that reliably and consistently identifies the best clones. By providing earlier answers and better growing conditions, we ensure greater accuracy in fewer steps, reducing the risk of rogue copies and enabling laboratories to discover the next breakthrough much faster and have a positive impact on human health. “I help.”
This system combines several trusted Beckman Coulter Life Sciences technologies, including microbial reactors, liquid handling, antibody titer and cell health (cell count and viability) measurement, into one advanced platform, giving laboratory managers more control over the best clone screening. It provides an effective and high-throughput method. This allows monitoring of up to 96 bioreactors with parallel pH control, fed-batch cultivation and individual gas handling.
Automated tasks provide at least 3 days of downtime during the experiment. Online, non-invasive pH, dissolved oxygen (DO) and biomass measurements provide continuous control of critical growing parameters. Cell concentration, viability and titer concentration are measured in situ to ensure informed selection of top clones. Learn more about the Cydem VT automated clone screening system. Click here.
